Aardvark Therapeutics, Inc. Common Stock (AARD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) has a cash flow conversion efficiency ratio of -0.151x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.52 Million) by net assets ($122.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aardvark Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Aardvark Therapeutics, Inc. Common Stock debt and liabilities for a breakdown of total debt and financial obligations.
Aardvark Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aardvark Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apollo Food Holdings Bhd
KLSE:6432
|
0.007x |
|
Ann Joo Resources Bhd
KLSE:6556
|
0.139x |
|
Rekor Systems Inc
NASDAQ:REKR
|
-0.133x |
|
Alcatel Lucent Teletas Telekomunikasyon AS
IS:ALCTL
|
-0.122x |
|
Eastern Water Resources Development and Management Public Company Limited
F:7ES1
|
0.033x |
|
Distribuidora de Gas Cuyana SA
BA:DGCU2
|
0.087x |
|
Mitrabara Adiperdana PT
JK:MBAP
|
-0.004x |
|
Assertio Therapeutics Inc
NASDAQ:ASRT
|
-0.319x |
Annual Cash Flow Conversion Efficiency for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Aardvark Therapeutics, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-54.64 Million | $-18.09 Million | 0.331x | +97.79% |
| 2023-12-31 | $-34.80 Million | $-5.82 Million | 0.167x | -55.68% |
| 2022-12-31 | $-27.92 Million | $-10.54 Million | 0.378x | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more